Neuromyelitis optica spectrum disorders (NMOSDs) are blindness-causing neuritis. In NMOSD patients, NMO-IgG evokes astrocytopathy that in turn causes demyelination. While measurement of NMO-IgG titer will help neurologists make the diagnosis of NMOSDs, it is not sufficient to evaluate the severity of astrocytopathy. In this study, we compared the different levels of an astrocyte biomarker in cerebrospinal fluid of NMOSD patients with good or poor recovery, and then linked their differences to the changes in remyelinating promoter (CXCL12) levels. Our results indicate that NMO-IgG down-regulated CXCL12 and impaired the remyelinating process, this may be a mechanism contributing to the poor recovery of NMOSDs.
Keywords: Aquaporin 4 (AQP4); CXC-motif ligand 12 (CXCL12); Glial fibrillary acidic protein (GFAP); Neuromyelitis optica spectrum disorders (NMOSDs); Tumor necrosis factor α (TNFα).
Copyright © 2015. Published by Elsevier B.V.